These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23149818)

  • 1. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
    Perna SK; De Angelis B; Pagliara D; Hasan ST; Zhang L; Mahendravada A; Heslop HE; Brenner MK; Rooney CM; Dotti G; Savoldo B
    Clin Cancer Res; 2013 Jan; 19(1):106-17. PubMed ID: 23149818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
    Perna SK; Pagliara D; Mahendravada A; Liu H; Brenner MK; Savoldo B; Dotti G
    Clin Cancer Res; 2014 Jan; 20(1):131-9. PubMed ID: 24097874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
    Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a protocol for rapidly expanding Epstein-Barr-virus-specific cytotoxic T cells with enhanced cytotoxicity.
    Fang CH; Cheng YF; Lin SR; Lai WY; Liao LR; Chiu YL; Lee JM
    BMC Cancer; 2024 Aug; 24(1):980. PubMed ID: 39118069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
    Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
    Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
    Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
    Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
    Quintarelli C; Vera JF; Savoldo B; Giordano Attianese GM; Pule M; Foster AE; Heslop HE; Rooney CM; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(8):2793-802. PubMed ID: 17638856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBV-related lymphomas: new approaches to treatment.
    Kanakry JA; Ambinder RF
    Curr Treat Options Oncol; 2013 Jun; 14(2):224-36. PubMed ID: 23549980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
    Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
    J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
    Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
    J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
    Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
    Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy to improve function of T cells for adoptive immunotherapy.
    Quintarelli C; Savoldo B; Dotti G
    Methods Mol Biol; 2010; 651():119-30. PubMed ID: 20686964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
    Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
    Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
    Gerdemann U; Katari U; Christin AS; Cruz CR; Tripic T; Rousseau A; Gottschalk SM; Savoldo B; Vera JF; Heslop HE; Brenner MK; Bollard CM; Rooney CM; Leen AM
    Mol Ther; 2011 Dec; 19(12):2258-68. PubMed ID: 21915103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
    Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
    Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.